HALT-IT trial, Tranexamic acid for the treatment of gastrointestinal haemorrhage: an international randomised, double blind placebo controlled trial
The HALT‐IT trial will determine the effect of early administration of TXA on mortality, morbidity (re‐bleeding, non‐fatal vascular events), blood transfusion, surgical intervention and health status in patients with acute gastrointestinal bleeding.
A pragmatic, randomised, double blind, placebo controlled trial among 8,000 patients with significant gastrointestinal bleeding.
Patients with significant GI bleeds in whom the use of tranexamic acid is neither indicated nor contraindicated
Professor Iain Roberts (LSHTM)
Dr Matt Reed (RIE)
Dr Nick Church
Dr James Dear
Dr Kallirroi Kefala
Julia Grahamslaw – local EMeRGE study lead
ED research nurses
TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants. For further information, please contact the EMERGE team.
Identification and characterization of the clinical toxicology of novel psychoactive substances (NPS) by laboratory analysis of biological samples from recreational drug users.
Identification of Novel Psychoactive Substances (IONA)
ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections in the UK (CCP-UK)